Podcasts about diabetic macular edema

Interview with Arshad M. Khanani, MD, author of Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. Hosted by Neil Bressler, MD. Related Content: Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema

Interview with Arshad M. Khanani, MD, author of Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. Hosted by Neil Bressler, MD. Related Content: Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema

A JAMA study identified factors linked to loss to follow-up in diabetic retinopathy and macular edema patients, including male gender, distance from care, and sociodemographic disparities. In Vietnam, six months of levofloxacin therapy showed a non-significant reduction in multidrug-resistant tuberculosis, emphasizing the balance between benefits and tolerability. Finally, Phase II trial showed pancigromab's promise in addressing cancer cachexia, with weight gain and symptom improvement, supporting further research.

This podcast is published open access in Ophthalmology and Therapy and is fully citeable. You can access the original published podcast article through the Ophthalmology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40123-024-01053-3 All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Dr. Steve Edelman, an endocrinologist living with Type 1 diabetes, is joined by Dr. Nik London, an ophthalmologist specializing in retinal diseases such as Diabetic Retinopathy and Diabetic Macular Edema. Throughout this episode, they discuss eye complications and their effects on individuals with diabetes. They go into depth and breakdown Diabetic Retinopathy—a common eye complication found in individuals with diabetes. Diabetic retinopathy is a leading cause of blindness among individuals with diabetes, but through education, regular checkups, and advancements in treatment, the risk of vision loss can be significantly reduced. They explore how the condition can develop, its treatments, and the importance of regular eye checkups for individuals with diabetes. Dr. London shares his professional insights and knowledge on protecting eye health, advancements in retinal care, and how early detection can prevent vision loss among individuals with diabetes..Key Topics:What is diabetic retinopathy, and how does it develop?The different stages of diabetic retinopathy.What is Diabetic Macular Edema?How can DME be prevented?The importance of regular eye checkups for individuals with diabetes.How diabetes affects eye health and vision?Advances in the treatment of diabetic retinopathy Anti-VEGF injections.How do these injections work in regard to Diabetic Retinopathy?The different methods for preventing and treating diabetic retinopathy.How can early intervention save vision in patients with diabetes?Why early intervention is important when it comes to eye health.What to expect during a retinal exam and treatment process.Learn More:Video: Eye Complications – Prevention, Early Detection, and Aggressive TreatmentVideo: Routine Eye Exams: The What, When, How and WhyLearn more about DME and Vabysmo  ★ Support this podcast ★

Drs. David Eichenbaum and Priya Vakharia share their insights on biosimilars in the treatment of retinal disease in the United States.

Dr. Ira Spector, PhD is CEO and a Co-Founder of SFA Therapeutics ( https://sfatherapeutics.com/ ), a microbiome-derived biopharma company focused on new advancements in the treatment inflammatory diseases. Dr. Spector is an experienced drug developer, with over 30 years of experience. He has helped develop 34 approved drugs, including Enbrel, Effexor, Protonix, Prevenar-13, Mylotarg at Wyeth/Pfizer, where he was Vice President of Clinical Operations and Vice-Chief of Development. At Allergan, Dr. Spector helped develop Ozurdex for Diabetic Macular Edema and Retinal Venous Occlusion, Botox for Overactive Bladder, Botox for Chronic Migraine, Juvederm XL and Botox for Cerebral Palsy. Prior to Wyeth, he was Vice President and Partner at the PA Consulting Group. Before founding SFA Therapeutics, Dr. Spector was Executive Vice President of Analytics & Consulting at ICON. Dr. Spector holds BS degrees in Physics and Electrical Engineering from Washington University, where he was a Langsdorf Fellow, an MBA from Drexel University, and a PhD in Health Sciences from UMDNJ. Support the show

We discuss the treatment results of high dose aflibercept in the eyes in the most severe quartile of diabetic macular edema with Dr. Roger Goldberg of Walnut Creek, California.

We discuss the importance of intensive therapy of DME, when using aflibercept for DME, as suggested by a review of real world cases from the Vestrum  data base, with Dr. Ferhina Ali, Assistant Professor of Ophthalmology, New York Medical College

We discuss the use of a topical agent for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Research, Sierra Eye Associates, Associate Clinical Professor of Ophthalmology, University Nevada School of Medicine, Reno.

We discuss retinal drying in diabetic macular edema using the Iluvien implant with Dr. Michael Singer, Adjunct Professor, University of Texas Health Science Center, San Antonio.

We discuss the use of a novel treatment approach, senolytic therapy, for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Professor, USC Roski Eye Institute.

In this episode, Ayesha talked about how three more US states have filed a lawsuit against Eli Lilly over its proposed $13.5 million insulin pricing settlement. The states join six others who have been fighting Eli Lilly in court since 2017, claiming that the company hiked prices of its insulin product Humalog. The states say the $13.5 million settlement offer from Eli Lilly doesn't come close to the $1 billion worth of claims the company is facing. Hear more about the insulin pricing controversy in this episode.Ayesha also talked about the FDA approval of Regeneron's high dose Eylea (HD Eylea) for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). Hear about how high dose Eylea offers less frequent dosing regiments, and how it will be facing Roche's blockbuster eye injection Vabysmo.Read the full articles here:More US States Take on Eli Lilly in Court Over Proposed $13.5 Million Insulin Pricing SettlementRegeneron's High Dose Eylea Gets FDA Nod for Wet AMD and DMEFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In our latest update, we discuss the relative drying effects of faricimab and aflibercept in the treatment of diabetic macular edema with Dr. Roger Goldberg.

We review the one year results of a clinical trial using high dose aflibercept (8mg) for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Clinical Professor of Ophthalmology, USC Roski Eye Institute

To characterize diabetic macular edema (DME) incidence in fellow eyes of patients treated for DME in the study eye.

We discuss the use of the port delivery system for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Clinical Research, Sierra Eye Associates, Associate Clinical Professor, University of Nevada School of Medicine, Reno.

We discuss the use of corticosteroids, in particular, the dexamethasone implant in the management of diabetic macular edema with Dr. Kevin Blinder, Professor of Clinical Ophthalmology at Washington University School of Medicine, The Retina Institute.

Dr. Noemi Lois from Queens University in Belfast, UK discusses results of the DIAMONDS study, which was a prospective trial that looked into the effectiveness, safety, and cost-effectiveness of subthreshold micropulse laser (SML), compared with standard laser (SL), for diabetic macular edema (DME) with central retinal thickness (CRT) < 400 um. Referenced article: Lois N, Campbell C, Waugh N, Azuara-Blanco A, Maredza M, Mistry H, McAuley D, Acharya N, Aslam TM, Bailey C, Chong V, Downey L, Eleftheriadis H, Fatum S, George S, Ghanchi F, Groppe M, Hamilton R, Menon G, Saad A, Sivaprasad S, Shiew M, Steel DH, Talks JS, Doherty P, McDowell C, Clarke M; DIAMONDS Study Group. Diabetic Macular Edema and Diode Subthreshold Micropulse Laser: A Randomized Double-Masked Noninferiority Clinical Trial. Ophthalmology. 2023 Jan;130(1):14-27. doi: 10.1016/j.ophtha.2022.08.012. Epub 2022 Aug 13. PMID: 35973593.

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.

Please visit answersincme.com/MYD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses best practices in diagnosis and treatment of diabetic retinopathy and diabetic macular edema. Upon completion of this activity, participants should be better able to: Recognize best practices to optimize the prompt and accurate diagnosis of diabetic retinopathy (DR) and diabetic macular edema (DME); and Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME.

Please visit answersincme.com/YCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses anti-VEGF treatment of diabetic retinopathy with or without diabetic macular edema. Upon completion of this activity, participants should be better able to: Review the clinical impact of approved VEGF-targeted agents for the treatment of DR and DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME; and Outline patient-centered management approaches to enhance outcomes for patients with DR with or without DME receiving VEGF-targeted therapy.

Please visit answersincme.com/QND860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses integrating anti–vascular endothelial growth factor (anti-VEGF) agents into treatment strategies for diabetic retinopathy (DR) and diabetic macular edema (DME). Upon completion of this activity, participants should be better able to: Review the clinical impact of approved VEGF-targeted agents for the treatment of DR and DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME; and Outline patient-centered management approaches to enhance outcomes for patients with DR with or without DME receiving VEGF-targeted therapy.

Dr. Jhavery discusses results of DRCR Retina Protocol AC study which compared DME response to anti-VEGF injections in patients who received Aflibercept monotherapy vs those who started with Bevacizumab first and then switched to Aflibercept if needed.  Discussed article: Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK; DRCR Retina Network. Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med. 2022 Aug 25;387(8):692-703. doi: 10.1056/NEJMoa2204225. Epub 2022 Jul 14. PMID: 35833805.

Please visit answersincme.com/YCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses anti-VEGF treatment of diabetic retinopathy with or without diabetic macular edema. Upon completion of this activity, participants should be better able to: Review the clinical impact of approved VEGF-targeted agents for the treatment of DR and DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME; and Outline patient-centered management approaches to enhance outcomes for patients with DR with or without DME receiving VEGF-targeted therapy.

We discuss a novel mechanism of action for the treatment of diabetic macular edema and neovascular AMD with Phase I/II trial results Dr. Raj Maturi, Midwest Eye Institute, Indiana University School of Medicine.

We discuss treat and extend versus alternate dosing strategies to treat center involving diabetic macular edema with Dr. Varun Chaudhary, Chief of Ophthalmology, Hamilton Regional Eye Center and Professor, McMaster University.

Drs. Shriji Patel, Safa Rahmani, and Sarwar Zahid join for a journal club discussion of three recent publications in major ophthalmology journals:Aflibercept or Bevacizumab First for Diabetic Macular Edema (https://www.nejm.org/doi/full/10.1056/NEJMoa2204225)Gas Tamponade for Postoperative Vitreous Hemorrhage Prevention (https://www.ajo.com/article/S0002-9394(22)00251-3/fulltext)Positioning after Macular Hole Surgery (https://ophthalmologyretina.org/article/S2468-6530(22)00322-0/fulltext)Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, DORC, Genentech, and Regeneron. Drs. Patel, Rahmani, and Zahid have no relevant disclosures.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Please visit answersincme.com/MYD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses best practices in diagnosis and treatment of diabetic retinopathy and diabetic macular edema. Upon completion of this activity, participants should be better able to: Recognize best practices to optimize the prompt and accurate diagnosis of diabetic retinopathy (DR) and diabetic macular edema (DME); and Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME.

The Journal RETINA is devoted exclusively to diseases of the retina and vitreous.  These podcasts are intended to bring to its listeners summaries of selected articles published in the current issue of this internationally acclaimed journal.

Dr. Drew Carey is joined by Dr. Tayyeba Ali and Google Software Engineer Pinal Bavishi to discuss their research collaboration with Google Health on a deep learning system that detects diabetic macular edema from their Ophthalmology Retina article, “Deep learning to detect optical coherence tomography-derived diabetic macular edema from retinal photographs: a multicenter validation study” Link to Google Health video discussed in the show: https://www.youtube.com/watch?v=2XQZQR477fg Deep Learning to Detect OCT-derived Diabetic Macular Edema from Color Retinal Photographs. Liu, Xinle et al. Ophthalmology Retina , Volume 6, Issue 5, 398 – 410.

We discuss the two year results of the first bispecific agent for the treatment of diabetic macular edema with Dr. John Wells III, from Palmetto Retina Clinic.

Drs. MacCumber and Singer explore the complex nature of caring for patients with diabetic macular edema including factors that impact arriving at the initial diagnosis, getting patients to the appropriate eye healthcare professional, and initiating appropriate therapy. They also describe the clinical factors that impact their treatment decision choices.

We discuss a phase I study examining the effect of plasma kvllikrein inhibition on diabetic macular edema with Dr. Arshad Khanani, Sierra Eye Associates, University of Nevada Reno.

Episode 339: Journal Club Including Discussion of Outcomes after Retinectomy for Proliferative Vitreoretinopathy, Gender Influence on Peer Review Process, and Diabetic Macular Edema and Retinopathy Rates Among Medicare Beneficiaries.Drs. Avni Finn, Katherine Talcott, and Priya Vakharia join for a journal club discussion of three recent publications in major ophthalmology journals.Retinectomy Visual Outcomes (https://www.ajo.com/article/S0002-9394(22)00096-4/fulltext)Authorship Gender and the Peer-Review Process (https://www.ajo.com/article/S0002-9394(22)00075-7/fulltext)Trends in Diabetic Retinopathy and Macular Edema (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2789629)Relevant Financial Disclosures: None relevant.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Dr. Brian Roberts is a Senior VP and Head of Clinical Development at Rezolute which is developing first in class therapies in the treatment of metabolic diseases. In addition to working on a therapeutic for congenital hyperinsulinism, a rare disease, Rezolute is also in clinical trials with RZ402, an oral small molecule to treat diabetic macular edema which is showing an increase in prevalence due to the increase in the number of people suffering from diabetes. Brian explains, "DME or diabetic macular edema is a complication of diabetes. It's a subset of diabetic retinopathy. And like other complications of diabetes, the blood vessels in the eye become injured or corrupted. And this leads to inflammation in the leakage of fluid across the blood vessel into the eye. And in this case, into the macula of the retina, which is responsible for high-resolution vision. If that continues, it can result in progressive visual loss and even blindness." "Another problem with these therapies is that in some patients, they simply don't work. So the disease is not driven by vascular endothelial growth factor or VEGF. And so there really is a need for therapies that address a different mechanism and that allow the earlier treatment of disease before the disease gets difficult to control. And that's where our oral therapeutic with a different mechanism of action comes into play." "First and foremost, it represents a different mechanism, or a different way, to target the disease. RZ402 is a plasma kallikrein inhibitor. The kallikrein system is involved in the promotion of inflammation and vascular leakage. And it's part of normal physiology around the body to really promote the fight against infection or injury." @RezoluteBio #RezoluteBio #Biotech #DME #Medicines #Innovation #RareDisease #MetabolicDiseases #DiabeticMacularEdema #DiabeticRetinopathy RezoluteBio.com Download the transcript here

Dr. Brian Roberts is a Senior VP and Head of Clinical Development at Rezolute which is developing first in class therapies in the treatment of metabolic diseases. In addition to working on a therapeutic for congenital hyperinsulinism, a rare disease, Rezolute is also in clinical trials with RZ402, an oral small molecule to treat diabetic macular edema which is showing an increase in prevalence due to the increase in the number of people suffering from diabetes. Brian explains, "DME or diabetic macular edema is a complication of diabetes. It's a subset of diabetic retinopathy. And like other complications of diabetes, the blood vessels in the eye become injured or corrupted. And this leads to inflammation in the leakage of fluid across the blood vessel into the eye. And in this case, into the macula of the retina, which is responsible for high-resolution vision. If that continues, it can result in progressive visual loss and even blindness." "Another problem with these therapies is that in some patients, they simply don't work. So the disease is not driven by vascular endothelial growth factor or VEGF. And so there really is a need for therapies that address a different mechanism and that allow the earlier treatment of disease before the disease gets difficult to control. And that's where our oral therapeutic with a different mechanism of action comes into play." "First and foremost, it represents a different mechanism, or a different way, to target the disease. RZ402 is a plasma kallikrein inhibitor. The kallikrein system is involved in the promotion of inflammation and vascular leakage. And it's part of normal physiology around the body to really promote the fight against infection or injury." @RezoluteBio #RezoluteBio #Biotech #DME #Medicines #Innovation #RareDisease #MetabolicDiseases #DiabeticMacularEdema #DiabeticRetinopathy RezoluteBio.com Listen to the podcast here

Dr. David Dyer is the Chief Retina Specialist for Alimera Sciences, a publicly-traded company specializing in the development and commercialization of prescription ophthalmology treatments for the management of retinal diseases. Having high blood sugar over time can damage the retinal blood vessels that bring nutrients to the retina, creating diabetic retinopathy. Alimera has developed a delivery platform to inject their drug Iluvien into the eye to treat the resulting diabetic macular edema. David explains, "So with retinal diseases, you're usually talking about diseases within the nerve fiber layer of the retina, the retinal vessels, or in the tissue that is underneath the retina that supports some of the retinal function. And that includes diabetic retinopathy, macular degeneration, vein occlusions, sometimes you can get detachments of the retina, and there are many other disorders, but those are the most common." "The treatment for diabetic macular edema typically involves injecting medications into the eye. That sounds horrible, but we can actually numb up the eye, usually, with a series of numbing drops, and with a very tiny needle, we can inject medicine into the center of the eye, and that medicine diffuses into the retina." "Iluvien is a sustained-release steroid. It's a little pellet, like a little tiny piece of rice, and we can inject that into the eye in the office, and it slowly dissolves over a period of three years, and it releases a steroid into the eye. The steroid works specifically on diabetic macular edema or the swelling in the central vision, and it decreases swelling." @AlimeraSciences $ALIM #Iluvien #NewDayStudy #DMEandME #DiabeticMacularEdema #Ophthamology #Diabetes #Vision AlimeraSciences.com Download the transcript here

Dr. David Dyer is the Chief Retina Specialist for Alimera Sciences, a publicly-traded company specializing in the development and commercialization of prescription ophthalmology treatments for the management of retinal diseases. Having high blood sugar over time can damage the retinal blood vessels that bring nutrients to the retina, creating diabetic retinopathy. Alimera has developed a delivery platform to inject their drug Iluvien into the eye to treat the resulting diabetic macular edema. David explains, "So with retinal diseases, you're usually talking about diseases within the nerve fiber layer of the retina, the retinal vessels, or in the tissue that is underneath the retina that supports some of the retinal function. And that includes diabetic retinopathy, macular degeneration, vein occlusions, sometimes you can get detachments of the retina, and there are many other disorders, but those are the most common." "The treatment for diabetic macular edema typically involves injecting medications into the eye. That sounds horrible, but we can actually numb up the eye, usually, with a series of numbing drops, and with a very tiny needle, we can inject medicine into the center of the eye, and that medicine diffuses into the retina." "Iluvien is a sustained-release steroid. It's a little pellet, like a little tiny piece of rice, and we can inject that into the eye in the office, and it slowly dissolves over a period of three years, and it releases a steroid into the eye. The steroid works specifically on diabetic macular edema or the swelling in the central vision, and it decreases swelling." @AlimeraSciences $ALIM #Iluvien #NewDayStudy #DMEandME #DiabeticMacularEdema #Ophthamology #Diabetes #Vision AlimeraSciences.com Listen to the podcast here

The fluocinolone implant at 3 years is a useful modality for treating diabetic macular edema. Discussion with Dr. Michael Singer, Adjunct Professor University of Texas at San Antonio.

Guest: Eser Adiguzel, PhD (Novartis) Guest: Randy Wong, MD (Novartis) A common complication of diabetes is diabetic macular edema (DME). Of the 463 million people worldwide aged 29 to 79 years old living with diabetes, many will develop diabetic retinopathy at about a rate of 27 percent. And of those 27 percent, a smaller subset will develop DME.1,2 Given its high prevalence, it's important to understand its pathophysiology, clinical features, challenges, and management approaches, which is why Drs. Eser Adiguzel and Randy Wong are here to share their insights on DME. International Diabetes Federation. Diabetes Atlas 9th Edition. 2019. Thomas RL, et al. Diabetes Res Clin Pract. 2019 Nov; 157:107840. 181534 2/22

Diabetes is a major public health issue and every person diagnosed with diabetes is at risk of developing diabetic eye disease. Diabetic macular edema is a common complication of diabetic eye disease, which occurs when blood vessels in the retina are damaged and leak fluid into the macula causing blurry central vision. On this episode of ASRS's Retina Health for Life,  Dr. Diana Do of the Byers Eye Institute at the Stanford University School of Medicine joins Dr. Timothy Murray to discuss the importance of early diagnosis and immediate treatment of diabetic macular edema by a retina specialist which can prevent irreversible vision loss and blindness.  Resources: Access a downloadable fact sheet on Diabetic Macular Edema here: www.asrs.org/patients/retinal-diseases/20/macular-edema 

Drs Kaiser and Garweg discuss the latest strategies for optimizing treatment outcomes for patients with diabetic macular edema (DME). Credit available for this activity expires: [11/02/22] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/961983?src=mkm_podcast_addon_961983

CME credits: 0.25 Valid until: 21-05-2022 Claim your CME credit at https://reachmd.com/programs/cme/frontiers-diabetic-macular-edema-durable-suppression-addressing-health-disparities/12568/ Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving upon the durability of VEGF suppression. These new treatments that go beyond the current standard of care may help reduce treatment burdens and ultimately improve vision outcomes in DME. Join our two experts, Dr. Christina Weng and Dr. Arshad Khanani, as they discuss these emerging agents, their mechanisms of action, and the latest available data.

CME credits: 0.25 Valid until: 21-05-2022 Claim your CME credit at https://reachmd.com/programs/cme/frontiers-diabetic-macular-edema-durable-suppression-addressing-health-disparities/12568/ Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving upon the durability of VEGF suppression. These new treatments that go beyond the current standard of care may help reduce treatment burdens and ultimately improve vision outcomes in DME. Join our two experts, Dr. Christina Weng and Dr. Arshad Khanani, as they discuss these emerging agents, their mechanisms of action, and the latest available data.

CME credits: 0.25 Valid until: 19-05-2022 Claim your CME credit at https://reachmd.com/programs/cme/frontiers-diabetic-macular-edema-addressing-health-disparities-and-other-barriers-optimal-outcomes/12526/ Diabetic macular edema and diabetic retinopathy are 2 of the most common vision complications associated with diabetes. Moreover, diabetic retinopathy is the leading cause of vision loss among adults. We know that screening works, and we have effective treatments, so why do we continue to see high rates of vision loss? Listen as our experts, Dr. Vivian Fonseca and Dr. Rishi Singh, navigate persisting disparities to determine which populations are most vulnerable, the barriers they face, and the potential for emerging strategies to improve screening and vision outcomes for all patients.

CME credits: 0.25 Valid until: 19-05-2022 Claim your CME credit at https://reachmd.com/programs/cme/frontiers-diabetic-macular-edema-addressing-health-disparities-and-other-barriers-optimal-outcomes/12526/ Diabetic macular edema and diabetic retinopathy are 2 of the most common vision complications associated with diabetes. Moreover, diabetic retinopathy is the leading cause of vision loss among adults. We know that screening works, and we have effective treatments, so why do we continue to see high rates of vision loss? Listen as our experts, Dr. Vivian Fonseca and Dr. Rishi Singh, navigate persisting disparities to determine which populations are most vulnerable, the barriers they face, and the potential for emerging strategies to improve screening and vision outcomes for all patients.

Dr. Jamie Dananberg, Chief Medical Officer of Unity Biotechnology discusses their strategy of selectively targeting senescent retinal vascular endothelial cells for a more long lasting effect on altering the pathophysiology of diabetic eye disease.

Join Drs Khanani, Wykoff, and Pieramici as they discuss the latest data on emerging therapies for DME Credit available for this activity expires: 4/2/2022 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/948380?src=mkm_podcast_addon_948380

Interview with Raj K Maturi, MD, and Jennifer K Sun, MD, authors of Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial and with Howard Bauchner, MD, Editor in Chief of JAMA

Interview with Raj K Maturi, MD, and Jennifer K Sun, MD, authors of Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial and with Howard Bauchner, MD, Editor in Chief of JAMA

Diabetic macular edema (DME), an accumulation of fluid in the retina from leaking blood vessels, is a major cause of visual acuity loss worldwide. Anti-vascular endothelial growth factor (VEGF) injections are a standard treatment today. VEGF is a protein that stimulates leakage from blood vessels, so blocking the protein can help reduce edema, or swelling of the retina. Joining the podcast is Lee Jampol, MD, who recently co-authored a study published in JAMA that found that waiting to start injection treatments until patients began to experience vision loss had similar outcomes when compared to starting injection treatments as soon as the condition was diagnosed. The injections are time consuming, costly and can carry the risk of harmful side effects, so waiting until the treatment is necessary has advantages for both the patient and providers.

Wellness Healing Protocols Reviewed by Dr Bill Deagle MD, Asthma, Multiple Sclerosis, Cataracts of Eyes, Diabetic Macular Edema, Alzheimer’s Dementia, Heart Vascular Disease, Heart Failure, Hyperthyroidism, Andropause, Joint Arthritis, Chronic Pain, Eye Floaters, Insomnia, Depression, Anxiety, Memory Cogntive Enhancement, Obesity, Diabetes, Hypothyroidism, Peripheral Neuropathy, Menopause, Hot Flashes, GERD, Hiatal Hernia, Dysbiosis, Maldigestion, Adrenal Exhaustion, Tendonopathy, Peripheral Neuropathy, ADHD ADD, Bipolar Depression, Anger Spells, Penile Pain at Glans, Prostatism, Diabetic Autonomic Overdrive, Tinnitus, RLS Restless Leg Syndrome, Food Allergies, Hayvfever Inhalanant Allergies, Arthritis, Osteoarthritis, Rheumatoid Inflmmatory Arthritis, Dermatitis, MRSA Skin Infections, Sinusitis, Periodontal Disease Cavitations,Dr Bill Deagle MD AAEM ACAM A4M, NutriMedical Report Show, www.NutriMedical.com, www.ClayandIRON.com, www.Deagle-Network.com,NutriMedical Report Show, For information regarding your data privacy, visit Acast.com/privacy See acast.com/privacy for privacy and opt-out information.

Host Cyrus Webb welcomes Dr. Charles C. Wykoff, Director of Research at Blanton Eye Institute, stops by #ConversationsLIVE to discuss the importance of our eye health during February which is recognized as Low Vision Awareness Month. He also talks about Wet Age-Related Macular Degeneration and Diabetic Macular Edema, the leading causes iof visual impairment in the U.S.

Dr. Charles Wykoff discusses results of DRCR protocol T ancillary study on plasma free VEGF concentrations after different intravitreal anti-VEGF injections for diabetic macular edema. Full reference of the discussed article: Jampol, L. M., A. R. Glassman, D. Liu, L. P. Aiello, N. M. Bressler, E. J. Duh, S. Quaggin, et al. "Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema." Ophthalmology  (Mar 7 2018).

Dr. Rajeev Muni describes the results of his research on the correlation of cytokine levels (VEGF, ICAM, etc) and the anatomical response to intravitreal ranibizumab for the treatment of diabetic macular edema. Full reference of the article: Hillier, R. J., Ojaimi, E., Wong, D. T., Mak, M. Y. K., Berger, A. R., Kohly, R. P., . . . Muni, R. H. (2018). Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2018.0179   Please send leave your comments in iTunes or send to theretinachannel@gmail.com

Dr. David Brown discusses his recent article in Ophthalmology about the role of targeted peripheral retinal laser photocoagulation to lower the treatment burden for diabetic macular edema. Full reference of the article:  Brown, D. M., Ou, W. C., Wong, T. P., Kim, R. Y., Croft, D. E., Wykoff, C. C., & Group, D. S. (2018). Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. Ophthalmology. doi:10.1016/j.ophtha.2017.11.026  

Marco Zarbin, MD, PhD, FACS

Elias Reichel, MD

Mary Beth Withers Wyss has been living with Diabetic Macular Edema for some time.  She went through a two year clinical trial of an experimental drug designed to treat DME.  She talks about her experience, about why clinical trials are perfect for a patient like her, and even why she is still a Cleveland Browns fan (to put the timeline into perspective, this was recorded before the Cincinnati Bengals had lost a game this season, and now they have lost two).Mary Beth frankly talks about the difficulties of living with DME, and living with the fact that the best treatment available to her involves injections directly into her eyes.Want to know about Diabetic Macular Edema from someone who's been there?  Want to know about clinical trials designed to find a viable treatment for DME?  Then you'll want to listen to this podcast. ©Stephen Shaul Reference Material - Click below for more information on this topic Learn more about diabetic macular edema (and other diabetes-related eye diseases), and find out more about the center where Mary Beth was treated during her clinical trial:National Eye Institute - Facts About Diabetic Eye DiseaseOhio State University department of Ophthalmology and Visual Science

Dr. Neil Bressler, James P. Gills Professor of Ophthalmology at Johns Hopkins University School of Medicine and Chief of the Retina Division at the Wilmer Eye Institute in Baltimore, Maryland will review the entire course and the goal of the program as well as review the CME information and learning objectives.

Dr. Susan B. Bressler, The Julia G. Levy, PhD, Professor of Ophthalmology, Division of Ophthalmology at Johns Hopkins University School of Medicine in Baltimore, Maryland will review evidence which will enable participants to recognize the limitations of current knowledge regarding the impact of vitrectomy for DME.

Drs. Neil and Susan Bressler from Johns Hopkins University School of Medicine will evaluate the different decision-making processes that guide management of macular edema from diabetes at presetntaion and follow-up

A conversation between Judy Kim, MD, and Neil M. Bressler, MD. Dr. Neil Bressler, chair of the Diabetic Retinopathy Clinical Research Network (DRCR.net), discusses this year

Introduction: To evaluate the effect of alpha-lipoic acid (ALA) on the occurrence of diabetic macular edema. Methods: Randomized, double-blind, placebo-controlled, multicenter, multinational study. Patients were randomized to the treatment group with 600 mg ALA per day or the placebo group. Every 6 months stereo fundus photographs, HbA1c levels, and an ophthalmological examination were documented. The primary endpoint was the occurrence of clinically significant macular edema (CSME) within a follow-up period of 2 years. Results: We randomized 235 patients with type II diabetes mellitus into the treatment group (mean age 58.0 years) and 232 into the placebo group (mean age 57.9 years). Mean HbA1c level was 8.1, with no significant differences between the treatment (mean 8.2, SD +/- 1.35) and placebo groups (mean 8.1, SD +/- 1.29). HbA1c values remained constant over time. In the treatment and placebo groups, 84 and 86 patients (35.7 and 37.1%) had insulin-dependent diabetes mellitus (IDDM) with a median duration of diabetes of 9.3 versus 9.0 years in the placebo group. Visual acuity remained unchanged during the entire trial. Concerning the primary endpoint, the study provided a negative result, i.e. 26/235 patients in the treatment group and 30/232 patients in the placebo group developed CSME. Confirmatory intention-to-treat analysis of the primary endpoint revealed no statistically significant difference between groups (log-rank test, p = 0.7108, HR = 0.9057 with CI = 0.5355-1.5317). Median follow-up was identical (2.00 years). Conclusions: A daily dosage of 600 mg ALA does not prevent the occurrence of CSME in IDDM patients. Copyright (C) 2011 S. Karger AG, Basel

Host Neil Bressler, MD, interviews Carl Baker, MD, and Michael Elman, MD. Conversation includes the use of OCT and angiography in evaluating for potential treatment of DME. Participants share their insight on which patients and situations are appropriate for focal grid laser, anti-VEGF drugs, intravitreal triamcinolone, or some combination based on several complicating factors and recent studies. (November 2010)

Background: Our purpose was to compare the effect of triamcinolone and bevacizumab (Avastin) on the retinal thickness and functional outcome in patients with diabetic macular edema. Methods and Materials: A collective of 32 patients, who had been treated by a single 4.0-mg intravitreal triamcinolone injection (group 1), was matched to 32 patients ('matched pairs'), who had received 3 injections of 1.25 mg of bevacizumab within 3 months in 4-week intervals (group 2). The outcome variables were changes in best corrected visual acuity (VA) and central retinal thickness 3 months after therapy. Results: Both groups did not differ regarding preoperative VA and central retinal thickness measured by optical coherence tomography. The baseline mean VA was 0.72 +/- 0.39 logMAR in group 1 and 0.73 +/- 0.39 logMAR in group 2 (p = 0.709). The mean central retinal thickness measured by optical coherence tomography was 548 +/- 185 mu m in group 1 and 507 +/- 192 mu m in group 2. While the patients in group 1 experienced a slight increase in VA of on average 0.7 lines following a single triamcinolone injection to a mean of 0.64 +/- 0.40 logMAR (p = 0.066) after 3 months, the patients in group 2 showed almost no effect on VA with an average increase of 0.2 lines to a mean VA of 0.72 +/- 0.30 logMAR (p = 0.948) following 3 intravitreal injections of bevacizumab. Comparing the effect on VA between both groups no statistically significant difference (p = 0.115) was noted. Concerning decrease in central retinal thickness both therapies were highly effective (p < 0.001 each), again, without statistically significant difference between the groups (p < 0.128). Conclusion: Our data suggest that a single triamcinolone injection may be as effective as a 3 times repeated intravitreal administration of bevacizumab for the treatment of diabetic macular edema. Further prospective trials should be performed. Copyright (C) 2010 S. Karger AG, Basel

Host: Bruce Bloom, DDS, JD Guest: Mary Elizabeth Hartnett, MD Almost a third of all type I and type II diabetics develop macular edema. Join host Dr. Bruce Bloom and his guest, ophthalmologist, researcher and vitreo-retinal surgeon Dr. Mary Elizabeth Hartnett, professor of opthamology at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the etiology and treatment of diabetic macular edema.

Host: Bruce Bloom, DDS, JD Guest: Mary Elizabeth Hartnett, MD Almost a third of all type I and type II diabetics develop macular edema. Join host Dr. Bruce Bloom and his guest, ophthalmologist, researcher and vitreo-retinal surgeon Dr. Mary Elizabeth Hartnett, professor of opthamology at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the etiology and treatment of diabetic macular edema.

Host: Bruce Bloom, DDS, JD Guest: Mary Elizabeth Hartnett, MD Almost a third of all type I and type II diabetics develop macular edema. Join host Dr. Bruce Bloom and his guest, ophthalmologist, researcher and vitreo-retinal surgeon Dr. Mary Elizabeth Hartnett, professor of opthamology at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the etiology and treatment of diabetic macular edema.

Guest: Dennis Shun-Chiu Lam, MB BS (HKU); MD (CUHK); FRCOphth (UK); FCOphth(HK)Professor and ChairDepartment of Ophthalmology & Visual SciencesThe Chinese University of Hong KongHong Kong

Go online to PeerView.com/EVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, an expert ophthalmologist and expert endocrinologist discuss the importance of diagnosing patients with diabetic retinopathy with or without diabetic macular edema early and how individualizing treatment improves outcomes. After participating in this activity, the learner will demonstrate the ability to: Describe current evidence-based recommendations for screening, diagnosis, and treatment of patients with suspected DR with or without DME, Facilitate timely diagnosis and treatment initiation, as appropriate, for patients with DR with or without DME, Incorporate strategies that overcome barriers to ensure timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR in patients with diabetes.

Go online to PeerView.com/DFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME activity, based on a recent live webcast, leading experts examine the vital role of primary care physicians in the management of patients who have or are at risk of DR and DME and offer practical insight on current screening recommendations, risk factor management, and novel treatment options to improve outcomes. Upon completion of this activity, participants should be better able to: Reconcile current guidance offered in evidence-based treatment recommendations regarding screening, diagnosis, and treatment of patients with suspected DR with or without DME, Counsel patients with DR with or without DME about the effects a timely diagnosis and initiation of appropriate treatment options can have on outcomes, Implement strategies that overcome barriers to ensure the timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR, Discuss newer treatment options in a manner that overcomes patient-related barriers and encourages them to seek care from ophthalmologic specialists.

Go online to PeerView.com/DFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME activity, based on a recent live webcast, leading experts examine the vital role of primary care physicians in the management of patients who have or are at risk of DR and DME and offer practical insight on current screening recommendations, risk factor management, and novel treatment options to improve outcomes. Upon completion of this activity, participants should be better able to: Reconcile current guidance offered in evidence-based treatment recommendations regarding screening, diagnosis, and treatment of patients with suspected DR with or without DME, Counsel patients with DR with or without DME about the effects a timely diagnosis and initiation of appropriate treatment options can have on outcomes, Implement strategies that overcome barriers to ensure the timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR, Discuss newer treatment options in a manner that overcomes patient-related barriers and encourages them to seek care from ophthalmologic specialists.

Go online to PeerView.com/EVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, an expert ophthalmologist and expert endocrinologist discuss the importance of diagnosing patients with diabetic retinopathy with or without diabetic macular edema early and how individualizing treatment improves outcomes. After participating in this activity, the learner will demonstrate the ability to: Describe current evidence-based recommendations for screening, diagnosis, and treatment of patients with suspected DR with or without DME, Facilitate timely diagnosis and treatment initiation, as appropriate, for patients with DR with or without DME, Incorporate strategies that overcome barriers to ensure timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR in patients with diabetes.

Go online to PeerView.com/DFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME activity, based on a recent live webcast, leading experts examine the vital role of primary care physicians in the management of patients who have or are at risk of DR and DME and offer practical insight on current screening recommendations, risk factor management, and novel treatment options to improve outcomes. Upon completion of this activity, participants should be better able to: Reconcile current guidance offered in evidence-based treatment recommendations regarding screening, diagnosis, and treatment of patients with suspected DR with or without DME, Counsel patients with DR with or without DME about the effects a timely diagnosis and initiation of appropriate treatment options can have on outcomes, Implement strategies that overcome barriers to ensure the timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR, Discuss newer treatment options in a manner that overcomes patient-related barriers and encourages them to seek care from ophthalmologic specialists.

Go online to PeerView.com/EVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, an expert ophthalmologist and expert endocrinologist discuss the importance of diagnosing patients with diabetic retinopathy with or without diabetic macular edema early and how individualizing treatment improves outcomes. After participating in this activity, the learner will demonstrate the ability to: Describe current evidence-based recommendations for screening, diagnosis, and treatment of patients with suspected DR with or without DME, Facilitate timely diagnosis and treatment initiation, as appropriate, for patients with DR with or without DME, Incorporate strategies that overcome barriers to ensure timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR in patients with diabetes.

Go online to PeerView.com/DFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME activity, based on a recent live webcast, leading experts examine the vital role of primary care physicians in the management of patients who have or are at risk of DR and DME and offer practical insight on current screening recommendations, risk factor management, and novel treatment options to improve outcomes. Upon completion of this activity, participants should be better able to: Reconcile current guidance offered in evidence-based treatment recommendations regarding screening, diagnosis, and treatment of patients with suspected DR with or without DME, Counsel patients with DR with or without DME about the effects a timely diagnosis and initiation of appropriate treatment options can have on outcomes, Implement strategies that overcome barriers to ensure the timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR, Discuss newer treatment options in a manner that overcomes patient-related barriers and encourages them to seek care from ophthalmologic specialists.

Go online to PeerView.com/EVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, an expert ophthalmologist and expert endocrinologist discuss the importance of diagnosing patients with diabetic retinopathy with or without diabetic macular edema early and how individualizing treatment improves outcomes. After participating in this activity, the learner will demonstrate the ability to: Describe current evidence-based recommendations for screening, diagnosis, and treatment of patients with suspected DR with or without DME, Facilitate timely diagnosis and treatment initiation, as appropriate, for patients with DR with or without DME, Incorporate strategies that overcome barriers to ensure timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR in patients with diabetes.

Go online to PeerView.com/DFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME activity, based on a recent live webcast, leading experts examine the vital role of primary care physicians in the management of patients who have or are at risk of DR and DME and offer practical insight on current screening recommendations, risk factor management, and novel treatment options to improve outcomes. Upon completion of this activity, participants should be better able to: Reconcile current guidance offered in evidence-based treatment recommendations regarding screening, diagnosis, and treatment of patients with suspected DR with or without DME, Counsel patients with DR with or without DME about the effects a timely diagnosis and initiation of appropriate treatment options can have on outcomes, Implement strategies that overcome barriers to ensure the timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR, Discuss newer treatment options in a manner that overcomes patient-related barriers and encourages them to seek care from ophthalmologic specialists.

Go online to PeerView.com/EVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, an expert ophthalmologist and expert endocrinologist discuss the importance of diagnosing patients with diabetic retinopathy with or without diabetic macular edema early and how individualizing treatment improves outcomes. After participating in this activity, the learner will demonstrate the ability to: Describe current evidence-based recommendations for screening, diagnosis, and treatment of patients with suspected DR with or without DME, Facilitate timely diagnosis and treatment initiation, as appropriate, for patients with DR with or without DME, Incorporate strategies that overcome barriers to ensure timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR in patients with diabetes.

Go online to PeerView.com/DFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME activity, based on a recent live webcast, leading experts examine the vital role of primary care physicians in the management of patients who have or are at risk of DR and DME and offer practical insight on current screening recommendations, risk factor management, and novel treatment options to improve outcomes. Upon completion of this activity, participants should be better able to: Reconcile current guidance offered in evidence-based treatment recommendations regarding screening, diagnosis, and treatment of patients with suspected DR with or without DME, Counsel patients with DR with or without DME about the effects a timely diagnosis and initiation of appropriate treatment options can have on outcomes, Implement strategies that overcome barriers to ensure the timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR, Discuss newer treatment options in a manner that overcomes patient-related barriers and encourages them to seek care from ophthalmologic specialists.

Go online to PeerView.com/EVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, an expert ophthalmologist and expert endocrinologist discuss the importance of diagnosing patients with diabetic retinopathy with or without diabetic macular edema early and how individualizing treatment improves outcomes. After participating in this activity, the learner will demonstrate the ability to: Describe current evidence-based recommendations for screening, diagnosis, and treatment of patients with suspected DR with or without DME, Facilitate timely diagnosis and treatment initiation, as appropriate, for patients with DR with or without DME, Incorporate strategies that overcome barriers to ensure timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR in patients with diabetes.

Go online to PeerView.com/DFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME activity, based on a recent live webcast, leading experts examine the vital role of primary care physicians in the management of patients who have or are at risk of DR and DME and offer practical insight on current screening recommendations, risk factor management, and novel treatment options to improve outcomes. Upon completion of this activity, participants should be better able to: Reconcile current guidance offered in evidence-based treatment recommendations regarding screening, diagnosis, and treatment of patients with suspected DR with or without DME, Counsel patients with DR with or without DME about the effects a timely diagnosis and initiation of appropriate treatment options can have on outcomes, Implement strategies that overcome barriers to ensure the timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR, Discuss newer treatment options in a manner that overcomes patient-related barriers and encourages them to seek care from ophthalmologic specialists.

Go online to PeerView.com/EVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, an expert ophthalmologist and expert endocrinologist discuss the importance of diagnosing patients with diabetic retinopathy with or without diabetic macular edema early and how individualizing treatment improves outcomes. After participating in this activity, the learner will demonstrate the ability to: Describe current evidence-based recommendations for screening, diagnosis, and treatment of patients with suspected DR with or without DME, Facilitate timely diagnosis and treatment initiation, as appropriate, for patients with DR with or without DME, Incorporate strategies that overcome barriers to ensure timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR in patients with diabetes.

Go online to PeerView.com/DFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME activity, based on a recent live webcast, leading experts examine the vital role of primary care physicians in the management of patients who have or are at risk of DR and DME and offer practical insight on current screening recommendations, risk factor management, and novel treatment options to improve outcomes. Upon completion of this activity, participants should be better able to: Reconcile current guidance offered in evidence-based treatment recommendations regarding screening, diagnosis, and treatment of patients with suspected DR with or without DME, Counsel patients with DR with or without DME about the effects a timely diagnosis and initiation of appropriate treatment options can have on outcomes, Implement strategies that overcome barriers to ensure the timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR, Discuss newer treatment options in a manner that overcomes patient-related barriers and encourages them to seek care from ophthalmologic specialists.

Go online to PeerView.com/EVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, an expert ophthalmologist and expert endocrinologist discuss the importance of diagnosing patients with diabetic retinopathy with or without diabetic macular edema early and how individualizing treatment improves outcomes. After participating in this activity, the learner will demonstrate the ability to: Describe current evidence-based recommendations for screening, diagnosis, and treatment of patients with suspected DR with or without DME, Facilitate timely diagnosis and treatment initiation, as appropriate, for patients with DR with or without DME, Incorporate strategies that overcome barriers to ensure timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR in patients with diabetes.